Dividend Aristocrats with low P/E’s and buying
recommendations originally published at long-term-investments.blogspot.com. We all love a growing
dividend and one of the most popular indices that cover the best dividend
growth stocks is the S&P
500 Dividend Aristocrats index.
The index has currently 54 constituents. My goal
in this article is to show you the currently cheapest stocks from the Dividend Aristocrats
Index with current buy or better ratings.
I know, it’s a little bit easy to trust others
work but the high-quality dividend stocks are already discovered. The only
thing we must do is to screen the current valuations and market opinions.
Only twelve stocks fulfilled both, a forward P/E
below 15 combined with a buy or better rating by brokerage firms. Half of the
results have a projected double-digit mid-term earnings growth forecast.
I really like Dividend Aristocrats but because
of the highly predictable business model and well known asset class, most of
them are no longer cheap. Only eighteen stocks have an expected P/E under 15!
That’s only one third of the full database and only around 20 percent of all Aristocrats
are recommended to buy.
Here are the best yielding Dividend Aristocrats:
Here are the best yielding Dividend Aristocrats:
If you would like to receive more dividend stock ideas and
the free Dividend Weekly, you should subscribe to my free e-mail list.
Alternatively, you can follow me on Facebook or Twitter.
AbbVie (NYSE:ABBV) has a market capitalization of $69.58 billion. The company employs 21,500 people, generates revenue of $18.380 billion and has a net income of $5.275 billion. AbbVie’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $7.614 billion. The EBITDA margin is 41.43 percent (the operating margin is 31.65 percent and the net profit margin 28.70 percent).
Financial Analysis: The total debt represents 58.03 percent of AbbVie’s assets and the total debt in relation to the equity amounts to 466.01 percent. Due to the financial situation, a return on equity of 68.98 percent was realized by AbbVie. Twelve trailing months earnings per share reached a value of $3.25. Last fiscal year, AbbVie paid $1.60 in the form of dividends to shareholders. Forward P/E: 13.61.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 13.49, the P/S ratio is 3.79 and the P/B ratio is finally 20.59. The dividend yield amounts to 3.65 percent and the beta ratio is not calculable.
 |
| Long-Term Stock Price Chart Of AbbVie (ABBV) |
 |
| Long-Term Dividend Payment History of AbbVie (ABBV) |
 |
| Long-Term Dividend Yield History of AbbVie (ABBV) |
Chevron (NYSE:CVX) has a market capitalization of $234.18 billion. The company employs 62,000 people, generates revenue of $241.909 billion and has a net income of $26.336 billion. Chevron’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $59.975 billion. The EBITDA margin is 24.79 percent (the operating margin is 19.15 percent and the net profit margin 10.89 percent).
Financial Analysis: The total debt represents 5.23 percent of Chevron’s assets and the total debt in relation to the equity amounts to 8.93 percent. Due to the financial situation, a return on equity of 20.30 percent was realized by Chevron. Twelve trailing months earnings per share reached a value of $12.34. Last fiscal year, Chevron paid $3.51 in the form of dividends to shareholders. Forward P/E: 9.93.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 9.82, the P/S ratio is 0.97 and the P/B ratio is finally 1.73. The dividend yield amounts to 3.30 percent and the beta ratio has a value of 0.82.
 |
| Long-Term Stock Price Chart Of Chevron (CVX) |
 |
| Long-Term Dividend Payment History of Chevron (CVX) |
 |
| Long-Term Dividend Yield History of Chevron (CVX) |
Nucor (NYSE:NUE) has a market capitalization of $14.83 billion. The company employs 22,200 people, generates revenue of $19.429 billion and has a net income of $593.13 million. Nucor’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $1.665 billion. The EBITDA margin is 8.57 percent (the operating margin is 4.39 percent and the net profit margin 3.05 percent).
Financial Analysis: The total debt represents 26.24 percent of Nucor’s assets and the total debt in relation to the equity amounts to 48.60 percent. Due to the financial situation, a return on equity of 6.65 percent was realized by Nucor. Twelve trailing months earnings per share reached a value of $1.30. Last fiscal year, Nucor paid $1.46 in the form of dividends to shareholders. Forward P/E: 13.98.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 35.72, the P/S ratio is 0.76 and the P/B ratio is finally 1.94. The dividend yield amounts to 3.15 percent and the beta ratio has a value of 1.03.
 |
| Long-Term Stock Price Chart Of Nucor (NUE) |
 |
| Long-Term Dividend Payment History of Nucor (NUE) |
 |
| Long-Term Dividend Yield History of Nucor (NUE) |
Johnson & Johnson (NYSE:JNJ) has a market capitalization of $245.62 billion. The company employs 127,600 people, generates revenue of $67.224 billion and has a net income of $10.514 billion. Johnson & Johnson’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $20.811 billion. The EBITDA margin is 30.96 percent (the operating margin is 20.49 percent and the net profit margin 15.64 percent).
Financial Analysis: The total debt represents 13.32 percent of Johnson & Johnson’s assets and the total debt in relation to the equity amounts to 24.94 percent. Due to the financial situation, a return on equity of 17.81 percent was realized by Johnson & Johnson. Twelve trailing months earnings per share reached a value of $4.50. Last fiscal year, Johnson & Johnson paid $2.40 in the form of dividends to shareholders. Forward P/E: 14.99.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 19.37, the P/S ratio is 3.65 and the P/B ratio is finally 3.66. The dividend yield amounts to 3.03 percent and the beta ratio has a value of 0.62.
 |
| Long-Term Stock Price Chart Of Johnson & Johnson (JNJ) |
 |
| Long-Term Dividend Payment History of Johnson & Johnson (JNJ) |
 |
| Long-Term Dividend Yield History of Johnson & Johnson (JNJ) |
Take a closer look at the full list of cheap Dividend Aristocrats with buy or better rating. The average P/E ratio amounts to 20.82
and forward P/E ratio is 12.94. The dividend yield has a value of 2.50 percent.
Price to book ratio is 4.03 and price to sales ratio 1.80. The operating margin
amounts to 17.58 percent and the beta ratio is 1.10. Stocks from the list have
an average debt to equity ratio of 0.77.
Here is the full table with
some fundamentals (TTM):
 |
| Cheap And Most Recommended Dividend Aristocrats (Click to enlarge) |
Do you like this article? If yes, please support us and hit the button for a Facebook Like, make a tweet or post a comment in the Dividend Yield
community! Thank you so much, we really appreciate it.
Related Stock Ticker Symbols:
ABBV, CVX, NUE,
JNJ, WMT, WAG, CAH, AFL, SWK, MDT, DOV, BEN
Selected Articles:
*I am long JNJ, WMT, WAG,
MDT. I receive no compensation to write about these specific stocks, sector or
theme. I don't plan to increase or decrease positions or obligations within the
next 72 hours.
For the other stocks: I
have no positions in any stocks mentioned, and no plans to initiate any
positions within the next 72 hours. I receive no compensation to write about
any specific stock, sector or theme.
